AbbVieABBV
NYSEPharmaceuticals
No cached AI snapshot yet for ABBV.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
57,000 employees1.77B shares outstandingdividend yield 3.50%
Next earnings ~May 5, 2026 · Ex-dividend Apr 15, 2026 · Dividend $1.73 quarterly
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Latest News
Canaccord raises Abbvie stock price target on strong quarter
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More
AbbVie signals $14.08-$14.28 2026 adjusted EPS as Skyrizi and Rinvoq outlook rises
AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
Related Stocksin Pharmaceuticals
Ready to see the live AI view on ABBV?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing ABBV side-by-side with live signals.